Evgen Pharma PLC (GB:TCF)
LSE:TCF
Want to see GB:TCF full AI Analyst Report?
Top Page
Evgen Pharma
(LSE:TCF)
Select Model
Select Model
Rating:50Neutral
Price Target:
0.26 p
▲(30.00% Upside)
Action:Reiterated
Date:04/15/26
The score is held back primarily by weak financial performance (ongoing losses and cash burn despite a debt-free balance sheet). Technicals are moderately supportive due to price strength versus moving averages, but the very overbought RSI raises near-term risk. Valuation is constrained by negative earnings and no dividend support.
Positive Factors
Debt-free balance sheet
A lack of reported debt materially reduces solvency and interest-cost risk, giving management flexibility to prioritize R&D and partnership negotiations over the next several months. This durable capital-structure strength lowers bankruptcy risk and improves options for non-dilutive financing or strategic deals.
Negative Factors
Persistent cash burn and negative cash flow
Consistent negative operating and free cash flows force reliance on external funding (equity, grants, or deals). Even with improvement in 2025, ongoing cash burn is a durable constraint that can dilute shareholders, delay programs, or pressure management to accept suboptimal partnerships within a 2–6 month horizon.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A lack of reported debt materially reduces solvency and interest-cost risk, giving management flexibility to prioritize R&D and partnership negotiations over the next several months. This durable capital-structure strength lowers bankruptcy risk and improves options for non-dilutive financing or strategic deals.
Read all positive factors
Evgen Pharma (TCF) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£5.05M
Dividend YieldN/A
Average Volume (3M)1.69M
Price to Earnings (P/E)―
Beta (1Y)0.83
Revenue GrowthN/A
EPS Growth85.56%
CountryUK
Employees9
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)0.00
Shares Outstanding2,148,963,600
10 Day Avg. Volume2,190,584
30 Day Avg. Volume1,685,058
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.20
Price to Sales (P/S)0.00
P/FCF Ratio-0.51
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)N/A
Evgen Pharma Business Overview & Revenue Model
Company Description
Theracryf Plc operates as a clinical-stage biotechnology firm, dedicated to advancing treatments for oncological diseases and various brain disorders affecting behavior. Its primary therapeutic asset, SFX-01, is currently progressing through Phase...
How the Company Makes Money
Evgen Pharma’s business model is typical of a clinical-stage biotech: it seeks to create value (and ultimately generate revenue) by advancing its drug candidates through clinical development and then monetizing them through partnering and/or comme...
Evgen Pharma Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
58
Neutral
Cash Flow
24
Negative
| Breakdown | TTM | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 396.00K | 442.00K | 0.00 | 194.00K |
| Gross Profit | -866.00K | -2.11M | 385.00K | 429.00K | -16.00K | -3.19M |
| EBITDA | -2.15M | -2.06M | -3.55M | -4.99M | -3.15M | -3.19M |
| Net Income | -2.01M | -1.94M | -3.14M | -4.04M | -2.73M | -2.67M |
Balance Sheet | ||||||
| Total Assets | 6.62M | 7.63M | 3.06M | 6.17M | 9.64M | 12.42M |
| Cash, Cash Equivalents and Short-Term Investments | 3.50M | 4.11M | 2.00M | 5.00M | 9.03M | 11.59M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.82M | 1.66M | 721.00K | 833.00K | 411.00K | 607.00K |
| Stockholders Equity | 4.80M | 5.97M | 2.34M | 5.34M | 9.23M | 11.81M |
Cash Flow | ||||||
| Free Cash Flow | -1.68M | -2.37M | -3.00M | -4.03M | -2.56M | -2.93M |
| Operating Cash Flow | -1.68M | -2.37M | -3.00M | -4.03M | -2.56M | -2.93M |
| Investing Cash Flow | -1.99M | -2.08M | 0.00 | 4.52M | 1.48M | -6.00M |
| Financing Cash Flow | 3.93M | 4.55M | 0.00 | 0.00 | 0.00 | 10.39M |
Evgen Pharma Technical Analysis
Positive
0.20
Price Trends
0.23
Positive
0.22
Positive
0.22
Positive
Market Momentum
<0.01
Negative
59.13
Neutral
50.00
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:TCF, the sentiment is Positive. The current price of 0.2 is below the 20-day moving average (MA) of 0.23, below the 50-day MA of 0.23, and below the 200-day MA of 0.22, indicating a bullish trend. The MACD of <0.01 indicates Negative momentum. The RSI at 59.13 is Neutral, neither overbought nor oversold. The STOCH value of 50.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:TCF.
Evgen Pharma Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | £215.34M | -39.06 | 90.29% | ― | ― | 69.01% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | £5.05M | -2.51 | -53.79% | ― | ― | 85.56% | |
47 Neutral | £29.79M | -6.01 | -284.01% | ― | ― | -105.65% | |
42 Neutral | £54.20M | -4.93 | -2807.75% | ― | ― | -28.29% | |
41 Neutral | £27.48M | -7.57 | -1397.43% | ― | ― | 36.67% | |
41 Neutral | £2.44M | -0.39 | ― | ― | 418.49% | 45.35% |
* Healthcare Sector Average
GB:TCF
Evgen Pharma
0.24
-0.03
-9.62%
GB:IMM
ImmuPharma
4.41
2.01
83.92%
GB:SAR
Sareum Holdings
21.50
6.75
45.76%
GB:SCLP
Scancell Holdings
20.75
11.35
120.74%
GB:HEMO
HemoGenyx Pharmaceuticals Plc
797.00
624.75
362.70%
GB:VAL
ValiRx plc
0.19
-0.49
-72.59%
Evgen Pharma Corporate Events
Business Operations and Strategy
TheraCryf to Host Investor Webinar as Lead Addiction Drug Nears Clinical Stage
Positive
Apr 21, 2026
TheraCryf plc, a biotech group headquartered in Alderley Park, Cheshire, develops therapies for addiction and neuropsychiatric disorders using a capital-light, virtual model that advances assets to early clinical or proof-of-concept stages before ...
Business Operations and StrategyProduct-Related Announcements
TheraCryf Hits Key Manufacturing Milestone for Lead Addiction Drug Ox-1
Positive
Apr 20, 2026
TheraCryf has completed successful Good Manufacturing Practice production of 2.57kg of clinical-grade drug substance for its lead orexin-1 receptor antagonist, Ox-1, clearing a key bottleneck ahead of planned Phase 1 trials in human volunteers. Th...
Business Operations and StrategyProduct-Related Announcements
TheraCryf Files New Process Patent to Extend Exclusivity for Lead Addiction Drug
Positive
Apr 16, 2026
TheraCryf plc, a UK biotechnology company developing treatments for addiction and other neuropsychiatric disorders, is advancing a pipeline led by a novel orexin-1 receptor antagonist aimed at binge eating, alcohol and substance use disorders. The...
Business Operations and StrategyM&A Transactions
TheraCryf Rejects Bid for Lead Neuropsychiatry Assets, Backs In-House Growth Strategy
Positive
Apr 14, 2026
TheraCryf plc has rejected a conditional, non-binding proposal to acquire its lead neuropsychiatry assets, including its Orexin-1 and dopamine transporter programmes, after the board unanimously decided the offer undervalued their current and futu...
Business Operations and StrategyProduct-Related Announcements
TheraCryf Advances Lead Addiction Drug to Final Preclinical Toxicology Milestone
Positive
Mar 23, 2026
TheraCryf has completed preclinical dose range finding studies for its lead orexin-1 receptor antagonist Ox-1, showing the drug was well tolerated at the highest regulatorily permitted dose of 1g per kilogram of body weight. The positive safety pr...
Business Operations and StrategyProduct-Related Announcements
TheraCryf Secures Final Major Ox‑1 Patent and Advances Addiction Drug Towards Clinical Stage
Positive
Jan 26, 2026
TheraCryf has secured a Notice of Allowance for its orexin‑1 (Ox‑1) addiction programme patent in Canada, completing composition-of-matter patent coverage across all major commercial markets including the US, Europe, Canada and key Asi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.